LIVINGSTON, N.J.--(BUSINESS WIRE)--Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that its third party data management consultants have confirmed that the results from the Company’s recently completed Phase II clinical trial evaluating vaginal lidocaine for the prevention and treatment of dysmenorrhea (a condition typified by painful menstruation) will be available on or before September 29, 2008. The Company had previously expected top line data to be available at the end of August.
